Comparative Pharmacology
Head-to-head clinical analysis: PEPCID AC versus ZANTAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID AC versus ZANTAC.
PEPCID AC vs ZANTAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
150 mg orally twice daily or 50 mg intravenously every 6-8 hours. Alternatively, 300 mg orally at bedtime.
None Documented
None Documented
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
2.5-3 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 20 hours in severe renal impairment (CrCl < 30 mL/min).
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Renal: 30% unchanged (tubular secretion); hepatic metabolism to N-oxide, S-oxide, and desmethyl ranitidine; biliary/fecal: minimal.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist